Latest news

Interim Report Q3 2024 Nanologica AB (publ)

8 November, 2024

FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) Operating loss for the quarter amounted to SEK -22,203 thousand (-10,292) and for the nine-month period to SEK -47,365 thousand (-34,324) Loss before tax for the quarter amounted to SEK -23,701 thousand (-11,554) and for the nine-month period to SEK -51,561 thousand (-38,318) Earnings per share before and after dilution were

CEO Comment Q3 2024

8 November, 2024

CEO COMMENT During the third quarter, we received our first recurring order for NLAB Saga® at a value of SEK 3.7 million from a customer in China. After the end of the quarter, we also received a supplementary order worth SEK 1.9 million from this customer, who is a producer of the fast-growing drug class GLP-1 analogues among other things. This is solid proof that NLAB Saga® works just as well as we expected also

Nanologica Announces Outcome of Rights Issue

16 October, 2024

Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of approximately SEK 99.4 million (the “Rights Issue”), for which the subscription period ended on October 14, 2024. The Rights Issue concerns so-called units, consisting of four shares and one free of charge warrant of series TO 2024/2025 (“Unit”). The Rights Issue has been subscribed to approximately 87.0 percent with and without the support of unit rights, of which

Nanologica Receives Supplementary Order Worth approximately SEK 1.9 Million from Returning Customer in China

4 October, 2024

Nanologica has received a supplementary order for the company’s silica-based purification media NLAB Saga® from the customer in China who at the end of September placed an order for NLAB Saga® at a value of approximately SEK 3.7 million. The value of this supplementary order amounts to approximately SEK 1.9 million. The customer is a pharmaceutical manufacturer that primarily produces peptides including GLP-1 analogues. In June this year, they placed a first order for NLAB

Teckning av units i pågående företrädesemission

4 October, 2024

Teckning av units kan ske via anmälningssedel eller länk nedan. Anmälningssedel units Nanologica AB https://app.verified.eu/web/bergs-securities/?company=Nanologica Teckningsperiod 30 september – 14 oktober 2024 Mer information om företrädesemissionen finns här.

Intervju med vd Andreas Bhagwani gällande den pågående företrädesemissionen

2 October, 2024

Intervju från 1 oktober 2024 med vd Andreas Bhagwani gällande den pågående emissionen.

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive